Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 277 to 278 of 278 entries
Sorted by: Best Match Show Resources per page
Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper.

British journal of haematology

Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, Hillmen P, Schuh AH.
PMID: 34607388
Br J Haematol. 2021 Oct 04; doi: 10.1111/bjh.17882. Epub 2021 Oct 04.

No abstract available.

Cite
Eyre TA, Riches JC, Patten PEM, et al. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. Br J Haematol. 2021;doi: 10.1111/bjh.17882.
Eyre, T. A., Riches, J. C., Patten, P. E. M., Walewska, R., Marr, H., Follows, G., Hillmen, P., Schuh, A. H. (2021). Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. British journal of haematology, . https://doi.org/10.1111/bjh.17882
Eyre, Toby A, et al. "Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17882
Eyre TA, Riches JC, Patten PEM, Walewska R, Marr H, Follows G, Hillmen P, Schuh AH. Richter transformation of chronic lymphocytic leukaemia: a British Society for Haematology Good Practice Paper. Br J Haematol. 2021 Oct 04; doi: 10.1111/bjh.17882. Epub 2021 Oct 04. PMID: 34607388.
Copy Download .nbib Format: NLM
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?.

Current oncology reports

Tang K, Schuh AC, Yee KW.
PMID: 34350512
Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9.

PURPOSE OF REVIEW: With the recent approval of multiple new drugs for the treatment of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such as daunorubicin and cytarabine ("3+7") induction chemotherapy, has been challenged. We review the...

Cite
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021;23(10):120doi: 10.1007/s11912-021-01108-9.
Tang, K., Schuh, A. C., & Yee, K. W. (2021). 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Current oncology reports, 23(10), 120. https://doi.org/10.1007/s11912-021-01108-9
Tang, Kenny, et al. "3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?." Current oncology reports vol. 23,10 (2021): 120. doi: https://doi.org/10.1007/s11912-021-01108-9
Tang K, Schuh AC, Yee KW. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?. Curr Oncol Rep. 2021 Aug 04;23(10):120. doi: 10.1007/s11912-021-01108-9. PMID: 34350512.
Copy Download .nbib Format: NLM
Showing 277 to 278 of 278 entries